Digestive Diseases and Sciences

, Volume 61, Issue 6, pp 1714–1720 | Cite as

Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia

  • Pierre BlaisEmail author
  • Michael Lin
  • Jennifer R. Kramer
  • Hashem B. El-Serag
  • Fasiha Kanwal
Original Article



Cardiovascular disease provides the greatest mortality risk in patients with nonalcoholic fatty liver disease (NAFLD). Clinical practice guidelines recommend statins to treat dyslipidemia in patients with NAFLD; however, the extent to which such patients receive statins has not been studied.


We conducted a structured medical record review to assess for appropriate statin use in patients in a Veterans Administration facility with dyslipidemia and NAFLD as well as a parallel cohort without NAFLD. Appropriate statin use was defined as receipt of statins without a clinically significant, unjustified dose change during the study period.


Of 255 patients with NAFLD and dyslipidemia, 152 (59.6 %) patients received appropriate statin care. Primary care providers (PCPs) recognized the presence of NAFLD in 106 patients (41.6 %). Among the 63 of 106 (59.4 %) patients who were on a statin at the time of detection, 24 (38.1 %) received a clinically significant dose reduction or discontinuation. Patients whose PCPs recognized the presence of NAFLD (adjusted OR = 0.34, 95 % CI = 0.18–0.64) were less likely to receive appropriate statin care than patients with undetected NAFLD. Also, patients with detected NAFLD were less likely than dyslipidemic patients without NAFLD to receive appropriate statin care (OR = 0.45, 95 % CI = 0.25–0.79).


Statins are underused in patients with NAFLD and dyslipidemia. The most important determinant for inappropriate statin use was PCP recognition of NAFLD. While these results need to be confirmed in non-VA healthcare systems, they highlight the need for efforts to enhance PCP knowledge of existing guidelines regarding statin use in NAFLD.


Nonalcoholic fatty liver disease Statin Cirrhosis Veterans Administration Automated data Ethnicity 



This work is funded in part by the Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413). Dr. El-Serag is also supported by National Institute of Diabetes and Digestive and Kidney Diseases K24-04-107.

Compliance with ethical standards

Conflict of interest



  1. 1.
    Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103:2263–2271.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Corey KE, Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:1077–1084.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609.CrossRefPubMedGoogle Scholar
  4. 4.
    Bays H, Cohen DE, Chalasani N, Harrison SA. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:247–257.Google Scholar
  5. 5.
    Cohen DE, Anania FA, Chalasani N. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:77C–81C.CrossRefPubMedGoogle Scholar
  6. 6.
    Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32:22–29.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci. 2014;59:1958–1965.CrossRefPubMedGoogle Scholar
  8. 8.
    Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690–695.CrossRefPubMedGoogle Scholar
  9. 9.
    Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287–1292.CrossRefPubMedGoogle Scholar
  10. 10.
    Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007;47:135–141.CrossRefPubMedGoogle Scholar
  11. 11.
    Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85:349–356.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol. 2014. doi: 10.1038/ajg.2014.134.PubMedGoogle Scholar
  13. 13.
    Husain N, Blais P, Kramer J, et al. Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther. 2014;40:949–954.CrossRefPubMedGoogle Scholar
  14. 14.
    Grundy SM, Becker D, Clark LT, et al. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–3421.CrossRefGoogle Scholar
  15. 15.
    US Food and Drug Administration. FDA Safety Communication: important safety label changes to cholesterol-lowering statin drugs. Accessed August 5, 2014.
  16. 16.
    Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106:71–77.CrossRefPubMedGoogle Scholar
  17. 17.
    Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post hoc analysis. Lancet. 2010;376:1916–1922.CrossRefPubMedGoogle Scholar
  18. 18.
    Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990–994.CrossRefPubMedGoogle Scholar
  19. 19.
    Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651–1658.CrossRefPubMedGoogle Scholar
  20. 20.
    Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2015. doi: 10.1016/j.cgh.2015.07.019.PubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Section of Gastroenterology and Hepatology, Department of MedicineBaylor College of MedicineHoustonUSA
  2. 2.Center for Innovations in Quality, Effectiveness and Safety (IQuESt)Michael E. DeBakey Veterans Affairs Medical CenterHoustonUSA
  3. 3.St. LouisUSA

Personalised recommendations